中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (8): 718-723.doi: 10.35541/cjd.20230054
宋志强 陈奇权 葛兰
收稿日期:
2023-02-06
修回日期:
2023-05-21
发布日期:
2023-08-07
通讯作者:
宋志强
E-mail:zhiqiang.song@hotmail.com
基金资助:
Song Zhiqiang, Chen Qiquan, Ge Lan
Received:
2023-02-06
Revised:
2023-05-21
Published:
2023-08-07
Contact:
Song Zhiqiang
E-mail:zhiqiang.song@hotmail.com
Supported by:
摘要: 【摘要】 特应性皮炎的发病机制复杂,主要与遗传背景、环境刺激、表皮屏障缺陷、免疫失调等因素有关。以Th2型炎症细胞因子以及JAK-STAT通路作为治疗靶点已成为特应性皮炎药物开发的热点。目前已有多个生物制剂和小分子药物成功用于特应性皮炎的治疗,标志其治疗已经迈入精准治疗和靶向治疗时代。
宋志强 陈奇权 葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023,56(8):718-723. doi:10.35541/cjd.20230054
Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.doi:10.35541/cjd.20230054
[1] | Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017[J]. Br J Dermatol, 2021,184(2):304⁃309. doi: 10.1111/bjd.19580. |
[2] | Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis[J]. Clin Dermatol, 2018,36(5):595⁃605. doi: 10.1016/j.clindermatol.2018.05.007. |
[3] | Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta⁃analysis[J]. Int J Dermatol, 2020,59(4):e75⁃e91. doi: 10.1111/ijd.14763. |
[4] | Li W, Man XY. Immunotherapy in atopic dermatitis[J]. Immunotherapy, 2022,14(14):1149⁃1164. doi: 10.2217/imt⁃2022⁃0054. |
[5] | Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease[J]. Nat Rev Drug Discov, 2022,21(1):21⁃40. doi: 10.1038/s41573⁃021⁃00266⁃6. |
[6] | Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease[J]. Nat Rev Drug Discov, 2016,15(1):35⁃50. doi: 10.1038/nrd4624. |
[7] | Awosika O, Kim L, Mazhar M, et al. Profile of dupilumab and its potential in the treatment of inadequately controlled moderate⁃to⁃severe atopic dermatitis[J]. Clin Cosmet Investig Dermatol, 2018,11:41⁃49. doi: 10.2147/CCID.S123329. |
[8] | Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis[J]. J Allergy Clin Immunol, 2021,148(4):927⁃940. doi: 10.1016/j.jaci.2021.08.009. |
[9] | Harb H, Chatila TA. Mechanisms of dupilumab[J]. Clin Exp Allergy, 2020,50(1):5⁃14. doi: 10.1111/cea.13491. |
[10] | Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016,375(24):2335⁃2348. doi: 10.1056/NEJMoa 1610020. |
[11] | Thaçi D, L Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate⁃to⁃severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)[J]. J Dermatol Sci, 2019,94(2):266⁃275. doi: 10.1016/j.jdermsci. 2019.02.002. |
[12] | Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis[J]. Am J Clin Dermatol, 2022,23(3):393⁃408. doi: 10.1007/s40257⁃022⁃00685⁃0. |
[13] | Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long⁃term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open⁃label phase IIa study and subsequent phaseⅢ open⁃label extension study[J]. Br J Dermatol, 2021,184(5):857⁃870. doi: 10.1111/bjd.19460. |
[14] | Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial[J]. Lancet, 2022,400(10356):908⁃919. doi: 10. 1016/S0140⁃6736(22)01539⁃2. |
[15] | Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review[J]. J Am Acad Dermatol, 2021,84(5):1339⁃1347. doi: 10.1016/j.jaad.2021.01.012. |
[16] | Akinlade B, Guttman⁃Yassky E, de Bruin⁃Weller M, et al. Conjunctivitis in dupilumab clinical trials[J]. Br J Dermatol, 2019,181(3):459⁃473. doi: 10.1111/bjd.17869. |
[17] | Papp KA, Hong CH, Lansang MP, et al. Practical management of patients with atopic dermatitis on dupilumab[J]. Dermatol Ther (Heidelb), 2021,11(5):1805⁃1828. doi: 10.1007/s13555⁃021⁃00586⁃w. |
[18] | Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phaseⅢ trials (ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2021,184(3):437⁃449. doi: 10.1111/bjd. 19574. |
[19] | Silverberg JI, Guttman⁃Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate⁃to⁃severe atopic dermatitis[J]. N Engl J Med, 2023,388(12):1080⁃1091. doi: 10.1056/NEJMoa2206714. |
[20] | Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus[J]. N Engl J Med, 2020,383(2):141⁃150. doi: 10.1056/NEJMoa1917006. |
[21] | Guttman⁃Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL⁃22 monoclonal antibody) in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double⁃blind, phase 2a trial[J]. J Am Acad Dermatol, 2018,78(5):872⁃881.e6. doi: 10.1016/j.jaad.2018.01.016. |
[22] | Chen YL, Gutowska⁃Owsiak D, Hardman CS, et al. Proof⁃of⁃concept clinical trial of etokimab shows a key role for IL⁃33 in atopic dermatitis pathogenesis[J]. Sci Transl Med, 2019,11(515):eaax2945. doi: 10.1126/scitranslmed.aax2945. |
[23] | Guttman⁃Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti⁃OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019,144(2):482⁃493.e7. doi: 10.1016/j.jaci.2018.11.053. |
[24] | Bao L, Zhang H, Chan LS. The involvement of the JAK⁃STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis[J]. JAKSTAT, 2013,2(3):e24137. doi: 10.4161/jkst. 24137. |
[25] | Le M, Berman⁃Rosa M, Ghazawi FM, et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis[J]. Front Med (Lausanne), 2021,8:682547. doi: 10.3389/fmed.2021.682547. |
[26] | Guttman⁃Yassky E, Teixeira HD, Simpson EL, et al. Once⁃daily upadacitinib versus placebo in adolescents and adults with moderate⁃to⁃severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double⁃blind, randomised controlled phase 3 trials[J]. Lancet, 2021,397(10290):2151⁃2168. doi: 10.1016/S0140⁃6736(21)00588⁃2. |
[27] | Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate⁃to⁃severe atopic dermatitis (JADE MONO⁃1): a multicentre, double⁃blind, randomised, placebo⁃controlled, phase 3 trial[J]. Lancet, 2020,396(10246):255⁃266. doi: 10.1016/S0140⁃6736(20)30732⁃ 7. |
[28] | Ständer S, Bhatia N, Gooderham MJ, et al. High threshold efficacy responses in moderate⁃to⁃severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents[J]. J Eur Acad Dermatol Venereol, 2022,36(8):1308⁃1317. doi: 10.1111/jdv.18170. |
[29] | Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate⁃to⁃severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE⁃AD5)[J]. J Am Acad Dermatol, 2021,85(1):62⁃70. doi: 10.1016/j.jaad.2021.02.028. |
[30] | Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double⁃blind, vehicle⁃controlled study and an open⁃label, long⁃term extension study[J]. J Am Acad Dermatol, 2020,82(4):823⁃831. doi: 10.1016/j.jaad.2019.12.015. |
[31] | Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies[J]. J Am Acad Dermatol, 2021,85(4):863⁃872. doi: 10.1016/j.jaad.2021. 04.085. |
[32] | Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults[J]. J Am Acad Dermatol, 2016,75(3):494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046. |
[33] | Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomised, double⁃blind, multicentre phase 3 trial[J]. Lancet, 2022,400(10348):273⁃282. doi: 10.1016/S0140⁃6736(22)01199⁃0. |
[34] | Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial[J]. JAMA Dermatol, 2021,157(9):1047⁃1055. doi: 10.1001/jamadermatol.2021.3023. |
[35] | Drucker AM, Morra DE, Prieto⁃Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta⁃analysis[J]. JAMA Dermatol, 2022,158(5):523⁃532. doi: 10.1001/jamadermatol.2022. 0455. |
[36] | Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition[J]. Mediterr J Rheumatol, 2020,31(Suppl 1):100⁃104. doi: 10.31138/mjr.31.1.100. |
[37] | Makhoba XH, Viegas C Jr, Mosa RA, et al. Potential impact of the multi⁃target drug approach in the treatment of some complex diseases[J]. Drug Des Devel Ther, 2020,14:3235⁃3249. doi: 10.2147/DDDT.S257494. |
[1] | 刘小扬 赵琰 蔡林 张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848. |
[2] | 郭昊 刘辉 张丽 朱冠男 王平 姚志荣 高兴华 陈耀龙. 特应性皮炎诊疗指南(专科医生版本、全科医生版本和患者版本)计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814. |
[3] | 陈春里 闫思聿 王丹 高丽华 谭丽娜 唐四元 刘伟 曾金容 鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831. |
[4] | 王珊 王星宇 舒虹 张斌 石航 杨欢 钱秋芳 马红艳 梁源 赵牧童 申春平 焦磊 田晶 汪洋 谷盈 孙婧 刘盈 李萍 王华 马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821. |
[5] | 周彤 耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793. |
[6] | 申春平 李萍 罗晓燕 梁源 刘盈 赵牧童 王珊 田晶 焦磊 汪洋 罗珍 余时娟 方晓 王华 马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762. |
[7] | 徐西利 李东宁 段函 王菲. 青少年及成人特应性皮炎患者血浆氨基酸代谢水平分析[J]. 中华皮肤科杂志, 2023, 56(8): 742-750. |
[8] | 张晓东 汪蔓雅 朱英杰 骆天德 刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769. |
[9] | 渠莉田 陈锦丛 程波 苏惠春. 特应性皮炎患者外周血单个核细胞转谷氨酰胺酶2的表达与相关炎症因子及疾病严重程度的相关性[J]. 中华皮肤科杂志, 2023, 56(7): 651-656. |
[10] | 蒋晓妍 高敏 张晓艳 刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692. |
[11] | 梁云生 黎展宏 伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558. |
[12] | 杨娜丽 许秋阳 吴含文 叶雅慧 朱吉玲 刘晶晶 李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524. |
[13] | 陈奇权 孔敏敏 杨显杰 王欢 李健 张名望 宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503. |
[14] | 苏畅 隋秀丽 刘瑞玲 曹毅群 姜虹 严彩蓉 王惠平 亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517. |
[15] | 李丽俏 彭聪 陈翔 李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511. |
|